Health Care

Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.

adminadmin
Dec 4, 2024 - 19:00
 0  0
Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial
Zepbound's greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Read More

Tags:

Previous Article

France's political chaos casts long shadow over economic growth

Next Article

Foot Locker issues gloomy holiday outlook, blames soft consumer demand

admin
admin

Related Posts

Goldman Sachs and American Express are among the leading companies for working parents in 2024, new study shows

Goldman Sachs and American Express are among the leadin...

admin May 15, 2024  0  8

New Covid FLiRT variants spark concerns of a summer spike

New Covid FLiRT variants spark concerns of a summer spike

admin May 22, 2024  0  5

We're encouraged by Abbott stock trading but discouraged by moves in Honeywell

We're encouraged by Abbott stock trading but discourage...

admin Jul 30, 2024  0  22